Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats by Wang, Xueqi et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2013
Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic
kidney disease progression in Han:SPRD rats
Wang, Xueqi; Zhang, Suhua; Liu, Yang; Spichtig, Daniela; Kapoor, Sarika; Koepsell, Hermann;
Mohebbi, Nilufar; Segerer, Stephan; Serra, Andreas L; Rodriguez, Daniel; Devuyst, Olivier; Mei,
Changlin; Wüthrich, Rudolf P
Abstract: Renal tubular epithelial cell proliferation and transepithelial cyst fluid secretion are key fea-
tures in the progression of polycystic kidney disease (PKD). As the role of the apical renal sodium-glucose
cotransporters in these processes is not known, we tested whether phlorizin inhibits cyst growth and de-
lays renal disease progression in a rat model of PKD. Glycosuria was induced by subcutaneous injection
of phlorizin in male heterozygous (Cy/+) and wild-type Han:SPRD rats. Phlorizin induced immediate
and sustained glycosuria and osmotic diuresis in these rats. Cy/+ rats treated with phlorizin for 5 weeks
showed a significant increase in creatinine clearance, a lower 2-kidneys/body weight ratio, a lower renal
cyst index, and reduced urinary albumin excretion as compared with vehicle-treated Cy/+ rats. Measure-
ment of Ki67 staining found significantly lower cell proliferation in dilated tubules and cysts of Cy/+ rats
treated with phlorizin, as well as a marked inhibition of the activated MAP kinase pathway. In contrast,
the mTOR pathway remained unaltered. Phlorizin dose dependently inhibited MAP kinase in cultured
tubular epithelial cells from Cy/+ rats. Thus, long-term treatment with phlorizin significantly inhibits
cystic disease progression in a rat model of PKD. Hence, induction of glycosuria and osmotic diuresis
(glycuresis) by renal sodium-glucose cotransporters inhibition could have a therapeutic effect in polycystic
kidney disease.Kidney International advance online publication, 29 May 2013; doi:10.1038/ki.2013.199.
DOI: 10.1038/ki.2013.199
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-78859
Accepted Version
Originally published at:
Wang, Xueqi; Zhang, Suhua; Liu, Yang; Spichtig, Daniela; Kapoor, Sarika; Koepsell, Hermann; Mo-
hebbi, Nilufar; Segerer, Stephan; Serra, Andreas L; Rodriguez, Daniel; Devuyst, Olivier; Mei, Changlin;
Wüthrich, Rudolf P (2013). Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic
kidney disease progression in Han:SPRD rats. Kidney International, 84(5):962-968. DOI: 10.1038/ki.2013.199
1  
 
 
Targeting of sodium–glucose cotransporters with 
phlorizin inhibits polycystic kidney disease 
progression in Han:SPRD rats 
 
Xueqi Wang1,2,3,6, Suhua Zhang1,2,4,6, Yang Liu2, Daniela Spichtig2, Sarika Kapoor1,2, Hermann Koepsell5, 
Nilufar Mohebbi1,2, Stephan Segerer1,2, Andreas  L. Serra1,2, Daniel Rodriguez2, Olivier Devuyst1,2, 
Changlin Mei3 and Rudolf  P. Wu¨ thrich1,2 
 
1Division of Nephrology, University Hospital, Zu¨rich, Switzerland; 2Institute of Physiology, University of Zu¨rich, Zu¨rich, Switzerland; 
3Department of Nephrology, Kidney Institute of PLA, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, PRC; 
4Department of Nephrology, Shanghai Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, PRC and 5Institute of 
Anatomy and Cell Biology, University of Wu¨rzburg, Wu¨rzburg, Germany 
 
 
 
Renal tubular epithelial cell proliferation and transepithelial 
cyst fluid secretion are key features in the progression of 
polycystic kidney disease (PKD). As the role of the apical renal 
sodium–glucose cotransporters in these processes is not 
known, we tested whether phlorizin inhibits cyst growth and 
delays renal disease progression in a rat model of PKD. 
Glycosuria was induced by subcutaneous injection of 
phlorizin in male heterozygous (Cy/ þ ) and wild-type 
Han:SPRD rats. Phlorizin induced immediate and sustained 
glycosuria and osmotic diuresis in these rats. Cy/ þ rats 
treated with phlorizin for 5 weeks showed a significant 
increase in creatinine clearance, a lower 2-kidneys/body 
weight ratio, a lower renal cyst index, and reduced urinary 
albumin excretion as compared with vehicle-treated Cy/ þ 
rats. Measurement of Ki67 staining found significantly lower 
cell proliferation in dilated tubules and cysts of Cy/ þ rats 
treated with phlorizin, as well as a marked inhibition of the 
activated MAP kinase pathway. In contrast, the mTOR 
pathway remained unaltered. Phlorizin dose dependently 
inhibited MAP kinase in cultured tubular epithelial cells from 
Cy/ þ rats. Thus, long-term treatment with phlorizin 
significantly inhibits cystic disease progression in a rat model 
of PKD. Hence, induction of glycosuria and osmotic diuresis 
(glycuresis) by renal sodium–glucose cotransporters inhibition 
could have a therapeutic effect in polycystic kidney disease. 
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Autosomal dominant  polycystic kidney disease (ADPKD) is 
characterized by the development of innumerable renal cysts 
which originate from the tubular epithelium of various 
nephron segments.1 Cystogenesis in ADPKD reflects epithelial 
dedifferentiation, increased proliferation, and abnormal fluid 
secretion.2 The compression of healthy adjacent parenchyma 
by the expanding cysts leads to progressive renal failure, with 
more  than  50%  of  the  patients  reaching  end-stage  renal 
disease during their lifetime.3 Insights into the pathophysio- 
logical processes that govern cyst development led to a 
growing number of drug candidates in ADPKD. In particular, 
several drugs targeting epithelial cell proliferation or the 
transport  processes that contribute  to intracystic fluid 
secretion  have  recently  been  proposed.  These  drugs 
include mammalian target of rapamycin (mTOR) inhibitors, 
somatostatin, and vasopressin type 2 receptor antagonists.4,5 
The dihydrochalcone phlorizin is a natural product and 
dietary constituent which is found in a number of fruit trees.6 
For decades, it  has been extensively used  as a  tool  for 
physiological research. Phlorizin’s principal pharmacological 
action is to produce renal glycosuria and—to a lesser degree— 
to block intestinal glucose absorption through inhibition of the 
Na þ –glucose cotransporters  (SGLTs) located apically in  the 
proximal tubules of the kidneys and the small intestinal mucosa. 
The administration of phlorizin to experimental animal models 
results in  profound  inhibition  of the  renal  SGLTs in  renal 
proximal tubules, resulting in marked glycosuria.6 
To the best of our  knowledge, the role of SGLTs in the 
pathogenesis of polycystic kidney disease (PKD)  has never 
been examined. We hypothesized that induction of glycosuria 
and  osmotic diuresis by inhibiting  renal SGLTs could slow 
cystogenesis and   renal  disease  progression.  To  test  this 
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hypothesis, we treated heterozygous (Cy/ þ ) Han:SPRD rats 
with phlorizin and investigated the effects of chronic glycuresis 
on parameters of renal function and cystogenesis. Our data 
demonstrate that phlorizin effectively retarded renal functional 
loss and cyst volume growth in this rat model of PKD. 
 
 
RESULTS 
Phlorizin treatment  induces glycosuria and osmotic diuresis 
in Han:SPRD rats 
Treatment  of  5-week-old male  heterozygous (Cy/ þ )  and 
wild-type ( þ / þ ) Han:SPRD rats with phlorizin (400 mg/ 
kg/day subcutaneous in propylene glycol) induced an 
immediate and sustained glycosuria. The glycosuria was 
accompanied by a threefold increase in urine output, 
reflecting   the   increased   osmolar   excretion   (Table   1; 
Figure 1a and b). In contrast, Cy/ þ and  þ / þ rats injected 
with the vehicle (propylene glycol) did not develop 
glycosuria. Plasma glucose levels did not change in response 
control  rats.  This is consistent  with  an  enhanced  tubular 
reabsorption of urea upon induction of osmotic diuresis. 
As albuminuria is a marker of renal disease severity in the 
Han:SPRD model of PKD, we determined the amount  of 
urinary  albumin  in  Cy/ þ  and   þ / þ  rats  treated  with 
phlorizin or vehicle by enzyme-linked immunosorbent  assay 
(ELISA) and  SDS–polyacrylamide gel  electrophoresis. 
Figure 2 shows that albumin excretion was higher in Cy/ þ 
compared  with  wild-type   þ / þ  rats,  as  expected.  The 
excretion of urinary albumin was significantly reduced upon 
treatment  of Cy/ þ rats  with  phlorizin.  After 5 weeks of 
treatment, the albumin excretion amounted to 2.7±0.7 mg/ 
day  in  vehicle-treated Cy/ þ  rats  vs. 1.0±0.4 mg/day  in 
phlorizin-treated animals (63.1% less in the phlorizin-treated 
group  compared  with the  vehicle-treated group,  Po0.01). 
to phlorizin (Table 1). Despite the massive polyuria, plasma 80       Cy/+ CON 
Cy/+ PHLO *** 
80       Cy/+ CON *** 
osmolality and plasma sodium and chloride concentrations 60       +/+ CON 60       +/+ CON *** 
were stable in Cy/ þ rats at days 17 and 35 of treatment, 
suggesting that the animals adequately compensated for the 
osmotic diuresis and did not get dehydrated. Of note, 
phlorizin-treated  Cy/ þ rats  displayed a slightly enhanced 
urinary sodium and chloride excretion rate compared with 
vehicle-treated rats, as well as a 6.7% weight difference at the 
end of the treatment period (Table 1). 
 
 
Effect of phlorizin  treatment  on renal function 
After 5 weeks of treatment with phlorizin, the plasma creatinine 
was 28% lower in male Cy/ þ rats compared with the vehicle- 
treated group, and  the creatinine clearance was 56% higher 
(Table 2; Figure 1c and d). Thus, despite increased urine output 
 
40 
 
20 
 
0 
 
 
0.4 
 
 
0.3 
 
 
0.2 
 
 
0.1 
      +/+ PHLO *** 
 
 
 
 
D0 D17 D35 
 
Cy/+ CON # 
Cy/+ PHLO 
+/+ CON 
      +/+ PHLO ** 
 
 
 
 
D0 D17 D35 
      +/+ PHLO 
40 
 
20 
 
0 
D0 D17 D35 
 
6 Cy/+ CON 
Cy/+ PHLO 
+/+ CON 
4      +/+ PHLO 
** 
2 # 
 
0 
D0 D17 D35 
and  lower body  weight, the  decline in  renal  function  was 
significantly attenuated in the phlorizin-treated rats. 
Plasma blood urea nitrogen values increased to a greater 
extent upon treatment of Cy/ þ rats with phlorizin compared 
with vehicle (Table 2). However, blood urea nitrogen values 
also  increased  upon   treatment   with  phlorizin  in   þ / þ 
Figure 1 | Diuresis, osmolar excretion, and renal function in 
control ( þ / þ ) and cystic (Cy/ þ ) male Han:SPRD rats treated 
with vehicle (propylene glycol; CON) or phlorizin  (PHLO). (a) 
Course of diuresis, (b) 24-h osmolar excretion, (c) plasma creatinine, 
and (d) creatinine clearance from baseline to days 17 and 35 of 
treatment. **Po0.01, ***Po0.001 when comparing Cy/ þ CON and 
Cy/ þ PHLO at each time point. #Po0.05 when comparing Cy/ þ and 
þ / þ group. 
 
 
Table 1 | Effect of phlorizin  treatment  on body weight, diuresis, and fluid and electrolyte parameters in Cy/ þ rats 
 
 Day 17    Day 35  
 Baseline CON  PHLO  CON  PHLO 
Number of animals (n) 17 7  10  7  10 
Age (in weeks) 5 7.5  7.5  10  10 
Total body weight (g) 94.5±2.5 212.8±8.7  186.7±7.3*  304.7±9.4  284.2±5.5* 
Diuresis (ml/day) 4.5±0.4 14.3±1.4  47.6±3.8***  23.6±2.9  65.0±2.2*** 
Posm (mosm/l) 300.5±16.4 306.3±5.5  306.7±7.9  310.2±4.1  314.2±16.9 
PNa þ (mmol/l) 143.7±2.8 144.9±3.6  144.4±3.1  144.3±3.7  144.7±8.8 
PCl - (mmol/l) 104.8±2.3 102.6±1.3  103.4±2.5  104.7±4.7  104.6±6.8 
Pglucose(mmol/l) 9.3±0.8 11.3±1.2  11.1±1.6  12.9±3.0  13.0±3.8 
Uosm (mosm/day) 8.3±2.4 18.7±4.0  47.0±7.3***  17.2±2.3  49.1±13.6*** 
Uglucose (mmol/day) o0.1 0.1±0.0  21.5±2.9***  0.1±0.0  18.0±4.6*** 
UNa þ (mmol/day) 0.6±0.2 1.2±0.2  1.7±0.1**  1.1±0.2  1.9±0.8** 
UCl - (mmol/day) 1.3±0.4 2.7±o.6  3.1±0.5  2.2±0.4  3.4±1.1*** 
Abbreviations: CON, vehicle (propylene  glycol) treated; PHLO, phlorizin. 
*Po0.05, **Po0.01, ***Po0.001 when comparing CON and PHLO at each time point. 
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Table 2 | Effect of phlorizin  on parameters of renal function in Cy/ þ and þ / þ rats 
 
BUN (mg/dl)   Creatinine (mg/dl) Creatinine clearance (ml/day) 
Group Time point (day) CON PHLO CON PHLO    CON PHLO 
Cy/ þ Baseline 39.7±5.6 41.0±4.7 0.14±0.03 0.15±0.03 2.04±0.50 1.67±0.68 
D17 53.8±4.4www 65.0±8.1*ww 0.18±0.04 0.17±0.03 3.40±0.37 3.86±0.93 
D35 77.8±14.8ww 76.6±13.0ww 0.35±0.08w 0.25±0.05* 2.34±0.81w 4.15±0.14* 
þ / þ Baseline 38.3±3.9 35.2±4.1 0.15±0.02 0.17±0.01 1.64±0.39 1.99±0.15 
D17 38.2±4.3 50.3±12.4 0.18±0.01 0.16±0.02 3.50±0.12 4.18±0.37 
D35 36.1±2.3 53.1±10.8* 0.22±0.03 0.21±0.03 4.56±1.26 4.82±1.01 
Abbreviations: BUN, blood urea nitrogen; CON, vehicle (propylene  glycol) treated; PHLO, phlorizin. 
*Po0.05  when comparing CON and PHLO  at each time point.  wPo0.05;  wwPo0.01;  wwwPo0.001  when comparing Cy/ þ and  þ / þ at each time point for the same 
treatment. 
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Figure 3 | Effect of phlorizin  on kidney weight and cyst index. 
Ratio of (a) 2-kidneys/body  weight (2K/BW) and (b) cyst index in male 
Cy/ þ rats treated daily for 5 weeks with vehicle (propylene glycol; 
CON; n ¼ 7) or phlorizin (PHLO, n ¼ 10). *Po0.05, ***Po0.001. 
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Figure 2 | Albumin excretion in Cy/ þ and þ / þ rats after 5 
weeks of treatment  with vehicle (propylene glycol; CON) or 
phlorizin  (PHLO). (a) Urine albumin concentration (Cy/ þ CON: 
n ¼ 7; Cy/ þ PHLO: n ¼ 10; þ / þ CON: n ¼ 5; þ / þ PHLO: n ¼ 3). 
**Po0.01; (b) Urine sample SDS–polyacrylamide gel electrophoresis. 
Each lane shows a urine sample of a single rat, each group shows 
representative samples from three rats. Loading volumes were 
corrected for diuresis and amounted to 15 ml for vehicle-treated rats, 
and 45 ml for phlorizin-treated  rats. Arrow shows the band for 
albumin. M, marker. 
 
This suggests that  the accompanying glomerular and 
proximal  tubular  damage was strongly attenuated  in 
phlorizin-treated Cy/ þ . 
 
Effect of phlorizin  treatment  on kidney weight and 
morphology 
After 5 weeks of treatment with phlorizin or vehicle, rats were 
killed and  the  kidneys were excised and  decapsulated for 
weight determination  and morphological analysis. The total 
weight of both kidneys amounted to 6.96±0.59 g in vehicle- 
treated  Cy/ þ (n ¼ 7) vs. 5.66±0.35 g in  phlorizin-treated 
Cy/ þ  rats  (n ¼ 10),  representing  a  difference of  18.7% 
(Po0.001). Figure 3a shows that the 2-kidneys/body weight 
ratio  was reduced  by 12.6% in  the  phlorizin-treated  rats 
 
 
 
 
 
 
 
200 μm 200 μm 
 
Figure 4 | Effect of phlorizin  on renal histology. Renal histology 
(periodic acid–Schiff) in (a, c) vehicle-treated (propylene glycol; CON) 
and (b, d) phlorizin-treated (PHLO) male Cy/ þ rats. Scale bar is 
2000 mm in a and b, and 200 mm in c and d. 
 
 
(Po0.001). Likewise the cyst index (determined on periodic 
acid–Schiff-stained sections) was reduced by 28.4% in 
phlorizin-treated rats (Po0.05). The cyst index data were 
confirmed by further histomorphological analysis of the 
kidneys, which demonstrated  that  phlorizin-treated  Cy/ þ 
rats had fewer and  smaller cyst profiles as compared  with 
vehicle-treated rats (Figure 4). 
 
Phlorizin inhibits  proliferation of cyst epithelium 
Immunostaining  for  Ki67 was used  to  examine  whether 
phlorizin  treatment  had  an  effect on  cystic epithelial cell 
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proliferation. Figure 5 demonstrates a marked increase in the 
positivity of nuclei in the cystic and non-cystic epithelium of 
Cy/ þ kidneys in comparison with wild-type þ / þ kidneys. 
Quantification of the Ki67-positive nuclei revealed that the 
number  of Ki67-positive nuclei was 39.8% lower in cystic 
epithelium and 23.8% lower in dilated tubules in phlorizin- 
versus  vehicle-treated  Cy/ þ  rats  (Table  3).  These  data 
suggest that phlorizin may directly affect cell proliferation. 
phosphorylation  and  the  ratio  of phosphorylated  to  total 
ERK and S6K were markedly increased in Cy/ þ compared 
with wild-type þ / þ rat kidneys. Of importance, phlorizin 
treatment  was associated with a significant decrease in the 
phosphorylation  of  ERK, whereas the  phosphorylation  of 
S6K was unchanged.  These data  suggest that  phlorizin 
differentially inhibits signaling cascades in the Cy/ þ kidneys. 
 
Effect of phlorizin  treatment  on mitogen-activated  protein 
kinase and mTOR signaling pathway 
We then  studied  the  effect of phlorizin  treatment  on  the 
phosphorylation  of two key kinases that  are known to  be 
activated in PKD, namely extracellular signal-regulated kinase 
(ERK; mitogen-activated protein  kinase (MAPK) pathway) 
and S6K (mTOR pathway). Figure 6 demonstrates that the 
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Figure 6 | Effect of phlorizin  on ERK and S6K phosphorylation. 
(a) Western blot analysis and (b) densitometry for mammalian target 
of rapamycin and mitogen-activated protein kinase pathway in þ / þ 
and Cy/ þ kidney. Cy/ þ rats show enhanced phosphorylation of 
extracellular signal-regulated  kinase (ERK) and S6K compared  with 
wild-type þ / þ animals. In phlorizin-treated Cy/ þ rats, the 
phosphorylation of ERK and the pERK/total ERK ratio is significantly 
reduced, whereas the phosphorylation of S6K and the pS6K/total  S6K 
ratio is unchanged. CON, propylene  glycol treated; GAPDH, 
glyceraldehyde-3-phosphate dehydrogenase; PHLO, phlorizin. 
*Po0.05, ***Po0.001. 
 
 
 
Phlorizin (μmol/l) 
 
pERK 
 
ERK 
+/+ Cy/+ 
 
0 0 10     100   1000 
 
50 μm 50 μm  
0.5 
+/+ 
Figure 5 | Representative areas of Ki67 immunohistochemical 
staining in Cy/ þ rat kidneys. (a) Cy/ þ CON (cyst), (b) Cy/ þ 
phlorizin (PHLO; cyst), (c) Cy/ þ CON (dilated tubule), (d) Cy/ þ PHLO 
(dilated tubule), (e) þ / þ CON, and (f) þ / þ PHLO. 
 
Table 3 | Effect of phlorizin  treatment  on Ki67 staining of 
Cy/ þ rat kidneys 
0.4 
 
0.3 
 
0.2 
 
0.1 
 
0.0 
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Phlorizin (μmol/l) 
Cy/+ 
 
Treatment 
CON 
(n ¼ 4) 
PHLO 
(n ¼ 7) 
Difference 
(%) P-value 
 
Figure 7 | Western blot analysis for phosphorylated extracellular 
signal-regulated kinase 1/2 (pERK; top) and total ERK (bottom) in 
Ki67-positive cells in dilated tubules  2.8±0.7 1.9±0.3 - 23.8 0.037 response to phlorizin treatment (0–1000 lmol/l) in cultured Cy/ þ 
Ki67-positive nuclei in cyst-lining 
e  pithelium 
5.8±2.3 3.5±1.5 - 39.8 0.029 tubular  epithelial  cell (TEC). TEC cultured from þ / þ kidneys 
served  as control. Bottom bar graph shows the densitometric  pERK/ 
Abbreviations: CON, vehicle (propylene  glycol) treated; PHLO, phlorizin. total ERK ratios. 
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Effect of phlorizin  on MAPK signaling pathway 
To test whether phlorizin has a direct effect on MAPK 
activation, we examined the effect of phlorizin in cultured 
tubular epithelial cells (TECs) derived from Cy/ þ kidneys. 
Figure 7 shows that ERK phosphorylation was constitutively 
upregulated in TECs derived from Cy/ þ cells, contrasting 
with the much weaker ERK phosphorylation, which is seen in 
TECs that  are  derived  from  wild-type  þ / þ rats.  Upon 
incubation of the cells with phlorizin (0–1000 mmol/l), there 
was a dose-dependent decrease of ERK phosphorylation. This 
suggests that  phlorizin via this direct effect on the MAPK 
signaling pathway could directly alter TEC activation and 
proliferation in PKD. 
 
DISCUSSION 
Treatment strategies for PKD with drugs that aim for renal- 
specific targets  may  provide  superior  efficacy and  fewer 
adverse events, compared with therapeutic agents that have a 
broader and less selective effect. The SGLT system may be one 
of these renal-specific targets in PKD, and SGLT inhibitors 
might have a potential benefit in PKD, either by directly 
affecting cell proliferation or indirectly via their osmotic 
diuresis  effect. Drugs  that  specifically inhibit  the  kidney- 
specific SGLT2 are currently being developed for glycemic 
control in type 2 diabetes.7,8 Most of the SGLT2 inhibitors are 
structurally derived from phlorizin, which is a powerful 
inhibitor  of  both  SGLT1 and  SGLT2, and  is  known  to 
produce massive glycosuria and osmotic diuresis in the rat.6,9 
Here, we show for the first time that chronic inhibition of 
SGLT and induction of glycosuria with phlorizin slows renal 
cystic disease progression in  the  Han:SPRD rat  model  of 
PKD.10 A 5-week treatment course with phlorizin resulted in 
the following: (1)  improved renal function,  as assessed by 
plasma  creatinine  and  creatinine  clearance measurements; 
(2) a reduction in urinary albumin excretion, which is a 
marker of disease progression in this model; (3) a lower total 
kidney weight and 2-kidneys/body weight ratio, correlating 
morphologically with smaller cysts and a lower cyst index; 
(4) decreased tubular and cystic epithelial cell proliferation, 
as assessed by Ki67 staining; (5) inhibition  of the activated 
MAPK pathway, as assessed by a lower p-ERK1/2 to  total 
ERK ratio,  both  in vivo and  in vitro. Thus, phlorizin- 
mediated induction  of glycosuria and the subsequent 
occurrence of osmotic diuresis (glycuresis) were associated 
with reduced cystic disease progression. 
The putative mechanisms by which phlorizin inhibits 
cystic renal disease progression may be manifold and must be 
discussed at several levels. First of all, phlorizin may directly 
inhibit cyst epithelial cell proliferation. This is suggested by a 
markedly reduced number of proliferating cyst epithelial cells 
in  phlorizin-treated  Cy/ þ rats.  In  addition,  our  in vitro 
experiments with cultured Cy/ þ TECs show that phlorizin 
has a direct effect on the MAPK pathway, which manifests as 
an inhibition  of ERK1/2 phosphorylation.  Second,  by 
inducing osmotic diuresis phlorizin might change the 
transepithelial transport  of fluid and  electrolytes in a way 
that inhibits cyst growth. From the present studies, however, 
it  is  not  possible to  provide  a  mechanism  how  osmotic 
diuresis could reverse fluid secretion into the cysts. Third,  a 
change  in  the  hormonal  environment  (in  particular  the 
inhibition   of   insulin   and   insulin-like   growth   factor-1 
production)  is likely to be caused by the loss of glucose in 
the urine  and/or  by a direct effect of phlorizin on insulin 
secretion. As insulin  and  insulin-like  growth  factor-1  are 
known to be implicated in cyst epithelial cell proliferation, 
the  reduced  cyst development  that  is seen with  phlorizin 
treatment  could  be partially explained by these hormonal 
changes.11,12 
Treatment  with  phlorizin  did  not  result  in  a  stop  or 
reversal of disease progression. The treatment was well 
tolerated by the rats and did not result in notable side effects, 
except for a threefold increase in the urine output, which was 
compensated by an appropriate  increase in fluid intake. As 
the activated MAPK13 and the mTOR pathway (reviewed in 
Torres et  al.14) critically contribute  to  the pathogenesis of 
PKD, one could postulate that SGLT inhibitors might be ideal 
drugs to combine with drugs that affect different signaling 
pathways, such as the mTOR pathway that was not affected 
by phlorizin in this study. We and others have previously 
shown that treatment with sirolimus15,16 or everolimus17 
significantly inhibited cyst growth and disease progression in 
Han:SPRD rats. The effect of mTOR inhibitors on cyst 
volume growth is only partial, perhaps because of the known 
compensatory   upregulation    of   the   MAPK   pathway.18 
Combining  SGLT inhibitors  with  mTOR  inhibitors  might 
therefore be a therapeutic  strategy worthwhile pursuing  in 
PKD. 
It might be of interest to oppose the effect of phlorizin 
(a glycuretic drug) and the effect of the vasopressin type 2 
receptor antagonist tolvaptan (an aquaretic drug), the latter 
of which is in phase 3 clinical development for the treatment 
of ADPKD.19,20 Both drugs target highly selective renal 
tubular transport  systems and produce a significant and 
sustained increase in urine output.  Similar to phlorizin, 
tolvaptan is also known to inhibit the ERK pathway but not 
the  mTOR  pathway.21,22  At  this  point,  it  is  not  known 
whether the vasopressin–cAMP axis is altered with phlorizin. 
In view of the primary  increase in the osmotic clearance, 
treatment with phlorizin could lead to increased endogenous 
AVP levels—an effect similar to that observed with long-term 
vasopressin type 2 receptor antagonism—23  and this could 
promote distal tubular cyst growth, an effect that might not 
be seen in Han:SPRD as the cysts are almost exclusively of 
proximal tubular origin, which are not supposed to be 
responsive to  vasopressin. Of note,  increasing fluid intake 
and urine output  experimentally by providing rats with 5% 
glucose in the drinking water also revealed a beneficial effect 
on cyst growth in a distal PKD model (PCK rat) but not in 
the proximal model (Han:SPRD rat).24  Thus, glycuretic and 
aquaretic drugs display similar and dissimilar effects on cyst 
volume progression and should be developed further as a 
future treatment for ADPKD. 
 
 
 
 
By now there is no evidence that chronic SGLT inhibition 
may potentially be deleterious for the kidney. Results from 
Sglt2 - / - knockout mice25 and more recently from Sglt1 - / - 
knockout mice26 have revealed that there is no alteration in 
renal function and morphology. As in phlorizin-treated rats, 
Sglt2 - / - mice display glycosuria, polyuria, and  increased 
food and fluid intake without differences in plasma glucose 
concentrations and glomerular filtration rate compared with 
wild-type mice. SGLT2 deficiency is also not associated with 
volume depletion, as shown by similar body weight, BP, and 
hematocrit.  Likewise, human  familial renal glycosuria that 
results from mutations in the SGLT2 gene is considered to be 
a benign condition.27  As far as we know, the renal safety of 
the SGLT2 inhibitor  dapagliflozin (in  clinical development 
for type 2 diabetes) is excellent, except for a slightly higher 
incidence of genitourinary infections.28 
In summary, we have shown that induction of glycosuria 
and osmotic diuresis (glycuresis) by inhibition  of the renal 
SGLT with phlorizin resulted in a significant retardation  of 
the cystic disease progression in the Han:SPRD rat  model 
of PKD. Further studies are in progress to assess the effect of 
glycosuria induction in additional models of PKD, including 
the ARPKD model in PCK rats. Whether this experimental 
strategy can be translated to human  ADPKD remains to be 
determined. 
 
MATERIALS AND METHODS 
Animals 
The Han:SPRD rat  colony was established in our  animal facility 
from a litter, which was obtained from the Rat Resource and 
Research Center (Columbia, MO). Heterozygous cystic (Cy/ þ ) and 
wild-type normal ( þ / þ ) rats were used in this study. Only male 
rats were used as cysts develop more rapidly in male compared with 
female rats. The regulatory commission for animal studies, a local 
government  agency, approved  the  study  protocol.  Rats had  free 
access to tap water and standard rat diet. 
 
 
Study design 
Treatment was started in 5-week-old male heterozygous Cy/ þ or 
wild-type þ / þ control Han:SPRD rats. Groups of 7–10 rats were 
used. Phlorizin (Sigma-Aldrich, Buchs, Switzerland) was dissolved 
in a solution of 60% propylene glycol in phosphate-buffered saline 
and  was injected subcutaneously at a dose of 400 mg/kg/day for 
5 weeks. Control rats were injected with the same volume of 60% 
propylene glycol in phosphate-buffered  saline. The dose of the 
phlorizin or the vehicle was adjusted daily according to the body 
weight of the rats. Blood and urine were collected at baseline (before 
treatment), at day 17 and 35 of treatment in all animals. All samples 
were stored at  - 20 1C before measurement. Rats were killed after 
5 weeks of treatment, and kidneys were harvested for further analysis. 
The Synchron LX System, UniCel DxC 600/800 System, and 
Synchron System AQUA CAL 1 and 2 (Beckman, Brea, CA) were 
used   for   the   quantitative   determination   of  glucose,  sodium, 
chloride, creatinine, and blood urea nitrogen concentrations in rat 
plasma and urine. Plasma and urine osmolalities were measured by 
using an Advanced freezing-point osmometer. 
The GenWay (San Diego, CA) rat albumin ELISA kit was used 
for urine albumin concentration measurements. The urine samples 
were diluted 500 times in the diluent solution. One-hundred 
microliter aliquots of albumin standard or urine sample were added 
into each well of precoated plates. Plates were incubated for 30 min 
at room temperature and were washed four times thereafter. Plates 
were then incubated with horseradish peroxidase–conjugated anti- 
albumin solution for 30 min at room temperature in the dark, and 
were washed again four times. Then 100 ml of 3,30 ,5,50 -tetramethyl- 
benzidine substrate solution was added into each well, and plates 
were incubated in the dark for 10 min at room temperature. Then 
100 ml stop solution was added, mixed well, and the absorbance at 
450 nm was determined  using a Tecan ELISA reader (Ma¨nnedorf, 
Zu¨ rich, Switzerland). 
 
Tissue sectioning, periodic acid–Schiff staining, and cyst 
index determination 
For the  histological examination,  one  of the  kidneys from  each 
animal was sliced perpendicularly to the long axis at B2-mm 
intervals. Slices from the midportion  of the kidneys were fixed in 
10% buffered formalin overnight. On the next day tissues were 
embedded in paraffin. Three-micrometer sections were stained with 
periodic acid–Schiff following routine  protocols. The stained 
sections were subjected to cyst index analysis, using the HistoQuest 
image analysis software (TissueGnostics, Vienna, Austria) to count 
the whole cortex region (total area, TA) and the cyst area (cyst area, 
CA) in the renal cortex. The cyst index was calculated as CA/ 
TAx100. 
 
Immunohistochemistry 
Immunohistochemistry  for  Ki67 was performed  on  3-mm  tissue 
sections. In brief, the tissue sections were deparaffinized and 
rehydrated. The antigen retrieval was performed in an autoclave 
oven. As primary antibody we used a mouse anti-Ki67 antibody (BD 
Pharmingen, San Jose, CA). After applying the primary antibody for 
1 h  the  sections  were  washed,  and   then   incubated   with  the 
biotinylated  secondary  antibody  (Vector,  Los  Angeles, CA)  for 
30 min. This was followed by the application of the ABC reagent 
(Vector), using 3,30 -diaminobenzidine with metal enhancement as 
the detection reagent. 
For each section we randomly chose 10 cysts, counted the 
number of Ki67-positive nuclei, and then averaged the number of 
Ki67-positive nuclei per cyst. We also chose 10 areas with dilated 
tubules and counted  the number  of Ki67-positive dilated tubules 
and  the  number  of  positive  Ki67 nuclei  per  tubule,  and  then 
averaged the Ki67-positive nuclei in each positive dilated tubule. 
 
Western blot analysis 
Kidneys were homogenized  with  ice-cold lysis buffer containing 
40 mmol/l  Hepes, 120 mmol/l  NaCl, 1 mmol/l  ethylenediaminete- 
traacetic  acid,  10 mmol/l   potassium   pyrophosphate,   10 mmol/l 
glycerol phosphate, 50 mmol/l NaF, 0.5 mmol/l NaVO3, 1% Triton- 
X 100, and protease inhibitor mixture (pH 7.6). Tissue lysates were 
cleared by centrifugation. Equal amounts of lysates were resolved by 
SDS–polyacrylamide  gel electrophoresis, transferred to nitrocellulose 
membranes, and probed with antibodies against ERK1/2Thr202/Tyr204, 
ERK1/2, p70 S6K Thr421/Ser424,  p70 S6K (all from  Cell Signaling 
Technology, Danvers, MA), and glyceraldehyde-3-phosphate dehy- 
drogenase. Sheep anti-mouse IgG-HRP and donkey anti-rabbit IgG- 
HRP were used as secondary antibodies. Quantification of 
phosphorylated  ERK1/2 and  p70 S6K expression was normalized 
for total ERK1/2 and p70 S6K, respectively, using a densitometer, 
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and the data are reported as ratio of phlorizin- versus vehicle-treated 
Cy/ þ and  þ / þ rats. 
 
Primary cultures of TECs from Cy/ þ rats 
Primary  cultures  of  TECs from  8-week-old  þ / þ  and  Cy/ þ 
kidneys were prepared  by mincing the kidneys and  digesting the 
tissues with 1 mg/ml  collagenase with gentle agitation  for 1 h  at 
37 1C. The suspension was allowed to sediment for 1 min. Cells were 
collected by harvesting the supernatant twice, and were then washed 
three times with 10% fetal bovine serum (FBS)/Hanks balanced salt 
solution. Isolated cells were resuspended in K1 medium (1:1 mixture 
of Dulbecco’s  modified Eagle’s medium  and Ham’s  F-12 medium 
supplemented with 5% FBS, 10 mmol/l HEPES, 42 mmol/l sodium 
bicarbonate, 50 ng/ml  insulin, 50 nmol/l  hydrocortisone,  50 ng/ml 
transferrin, 5 pmol/l triiodothyronine, 20 ng/ml rat EGF, 100 IU/ml 
penicillin, and 100 mg/ml  streptomycin). Cells were then seeded in 
collagen type 1–precoated culture dishes and grown to confluence. 
The medium was then changed to a K1 medium with 0.5% FBS for 
24 h, and the cells were then incubated with phlorizin (0–1000 mmol/l) 
for  24 h.  Lysates were  then   prepared   and   resolved  by  SDS– 
polyacrylamide gel electrophoresis and probed by western blot 
analysis with antibodies against ERK1/2Thr202/Tyr204 and total ERK1/2 
as described above. 
 
Statistical analysis 
Data are presented as means±s.d. Data were tested for statistically 
significant differences between treatment  groups by using the 
unpaired  two-tailed  t-test,  and  by  using  the  GraphPad  Prism 
version 5.0 software (GraphPad, San Diego, CA). Po0.05 was 
considered to indicate statistically significant differences. 
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